Bedside measurement of hemodynamic biomarkers with fast diffuse correlation spectroscopy
July 23-26, 2017
The objective assessment and characterization of cerebral tissue health at the bedside is a difficult but highly significant problem in the acute care of strokes and other brain injuries. Observational limitations of current technologies, which are better suited for radiological snapshots rather than continuous monitoring of cerebrovascular health, limit bedside optimization/augmentation of care to subjective judgements of observed neurological deficits. In recent years, Diffuse Correlation Spectroscopy (DCS) has proven to be an increasingly popular non-invasive optical technique to solve this technological gap by directly measuring and monitoring deep tissue blood flow. Here, we highlight DCS’s utility as a clinical bedside monitor of acute CBF changes in patients affected with ischemic stroke. In addition, we highlight the development and application of new ‘fast’ DCS instrument that uses conventional DCS sources/detectors, and optimized software computations to measure blood flow ‘waveforms’ at measurement rates of 50-100 Hz. A direct consequence of this new CBF data type is the ability to characterize potentially chronic biomarkers of cerebral tissue health at the bedside. First
Ashwin Parthasarathy, Arjun G. Yodh, W. Andrew Kofke, John A. Detre, Michael T. Mullen, Ramani Balu, Kimberly Gannon, and Wesley B. Baker, "Bedside measurement of hemodynamic biomarkers with fast diffuse correlation spectroscopy" in "Advances in Optics for Biotechnology, Medicine and Surgery XV", Peter So, Massachusetts Institute of Technology, USA Kate Bechtel, Triple Ring Technologies, USA Ivo Vellekoop, University of Twente, The Netherlands Michael Choma, Yale University, USA Eds, ECI Symposium Series, (2017). http://dc.engconfintl.org/biotech_med_xv/38
This document is currently not available here.